BOSTON, Mass., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will publish fourth quarter and full year 2025 financial results on Tuesday, February 24, 2026, after U.S. market close. About Standard BioTools Inc. Standard BioTools Inc. (Nasdaq: LAB), has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop better medicines faster. As a leading solutions provider, the company provides reliable ...

1 型糖尿病 （T1D） ，是一种慢性自身免疫疾病，其病因是免疫系统错误地攻击胰腺中产生胰岛素的 β 细胞 ，导致身体无法产生足够的胰岛素，进而导致血糖 水平升高。对于该疾病，目前尚无治愈方法，患者需要 终身依赖外源性胰岛素治疗 （通过注射或胰岛素泵） 来维持生命。 由于 T1D 的自身免疫特性，研究人员已开始探索涉及 T 细胞和 B 细胞的疗法，以期延缓或治愈该疾病。尽管免疫疗法的初步结果令人鼓舞，但这些治疗手段未 能满足当前临床维持持久正常血糖水平和摆脱胰岛素依赖的需求。这凸显了对 T1D 免疫生物学进行更深入研究的必要性。 2026 年 1 月 21 日， 中南大学湘雅二医院 李霞 教授、 赵斌 教授等，在 Nature 子刊 Nature Metabolism 上发表了题为： IL-21 mediates crosstalk between T cells and NK cells during the remission of type 1 diabetes 的研究论文。 该研究确定了 CD226 + CD56 dim CD16 + NK 细胞 是 1 型糖尿病 （T1D） 缓解期的关键生物标志物。 ...

Core Viewpoint - Kahn Swick & Foti, LLC has initiated an investigation into Charles River Laboratories International, Inc. following legal issues related to the company's supply chain practices and securities disclosures [1][3]. Group 1: Legal Issues - In February 2023, Charles River disclosed it received a subpoena from the U.S. Department of Justice regarding an investigation into the illegal importation of non-human primates, leading to a voluntary suspension of shipments from Cambodia [2]. - The suspension is expected to negatively impact the company's earnings for the year, reducing revenue growth by 200 to 400 basis points [2]. - Following the subpoena, Charles River and certain executives were sued in a securities class action lawsuit for failing to disclose material information, which is still ongoing [3]. Group 2: Investigation Focus - KSF's investigation is centered on whether Charles River's officers and/or directors breached their fiduciary duties to shareholders or violated state or federal laws [3].

Core Insights - Oncotelic Therapeutics has launched PDAOAI, a proprietary platform for extracting biologically meaningful signals from complex biomedical datasets without the need for bespoke large language models [1][3][4] - The platform provides access to a comprehensive TGF-β literature corpus, including over 125,000 PubMed abstracts, through a dedicated Discord research channel [1][13][14] Platform Functionality - PDAOAI enhances discovery speed and efficiency by structuring, embedding, clustering, and querying large volumes of biomedical literature and datasets [4][6] - It allows researchers to identify recurring biological themes and generate evidence-linked hypothesis candidates for experimental validation [6][20] Research Community Engagement - Oncotelic invites qualified researchers and industry partners to engage with PDAOAI and the TGF-β knowledge corpus via Discord, fostering collaboration and hypothesis exploration [3][14] - The platform supports interactive discussions around TGF-β-driven biology and translational opportunities [3][20] Validation and Impact - PDAOAI has contributed to multiple peer-reviewed publications, contextualizing survival-associated biological axes across various tumor microenvironments [8][10] - The platform's approach enables the identification of high-confidence biomarkers, such as TGFB2, which recur across different cancers, aiding in therapeutic strategies [9][10] Strategic Role - PDAOAI serves as a discovery and strategy engine within Oncotelic, augmenting expert judgment by surfacing signals for focused validation [15][20] - The platform is designed to operate in an era of data abundance, allowing teams to extract non-obvious signals without bias from single training sets [7][20]

Core Viewpoint - The article discusses the role of external risk factors, such as obesity and viral infections, in the development of neurodegenerative diseases, particularly Alzheimer's disease, and highlights the potential therapeutic target of oxidized macrophage migration inhibitory factor (oxMIF) in this context [1][3]. Group 1: Research Findings - A study published by researchers from Düsseldorf University identifies oxMIF as a drug target for Alzheimer's disease, linking external risk factors to tau pathology [2][3]. - The research indicates that the replication of HSV-1 (herpes simplex virus type 1) involves oxMIF, and that the compound PAV-174 can inhibit oxMIF, potentially blocking this process [8]. - The study found that oxMIF is abundant in the brains of sporadic Alzheimer's disease patients, suggesting its role as a molecular interface between external stressors and Alzheimer's pathology [8]. Group 2: Mechanisms and Implications - The interaction between viruses and host cell proteins can disrupt cellular protein homeostasis, increasing the risk of protein misfolding diseases [5]. - The identification of host proteins repurposed by viruses allows for the exploration of fundamental cellular activities in sporadic cell death events without relying on the viruses themselves [6]. - PAV-174 has shown effectiveness in reducing tau protein phosphorylation and aggregation in both in vitro and in vivo settings, independent of viral infection [6][8].

Legal & Compliance - Dana-Farber Cancer Institute to pay $15 million to settle fraud allegations [1] - Allegations include use of inaccurate or altered data and images in grant-funded biomedical research [1]

Core Viewpoint - Gene delivery is a critical component in life sciences research and gene therapy, acting as a "bridge" to deliver nucleic acids into cells for gene expression, knockdown, or editing, despite facing numerous challenges over time [3]. Group 1: Challenges in Traditional Gene Delivery Tools - Traditional tools for gene delivery, such as liposomes, viral vectors, and electroporation, have significant limitations, including low efficiency in primary immune cells and stem cells, high mutation risks, and potential damage to cell membranes [4][7]. Group 2: Innovative Solutions - Westlake University and the Westlake Condensate team have developed the ProteanFect gene delivery system, a novel non-viral, non-liposomal, and non-electroporation delivery method that mimics endogenous protein liquid-liquid phase separation for efficient nucleic acid encapsulation and delivery [6]. Group 3: Research Breakthroughs Enabled by ProteanFect - ProteanFect has supported multiple key research breakthroughs, including: 1. Immune cell function studies published in *Nature Cell Biology* and *Nature Microbiology*, demonstrating the system's ability to deliver siRNA to mouse primary T cells [9]. 2. Gene editing and metabolic validation studies published in *Signal Transduction and Targeted Therapy* and *Nature Communications*, showcasing efficient gene knockout in T cells [10]. 3. Exploration of special cell mechanisms published in *Nature Genetics* and *Journal of Advanced Research*, revealing insights into mitochondrial function and lymphocyte activity [11]. Group 4: Global Recognition and Impact - The scientific value of ProteanFect has been recognized internationally, with its technology selected for presentations at major conferences, including the American Society of Hematology and the International Society for Stem Cell Research [14]. The strategic partnership with OriGene marks its entry into the global mainstream research reagent supply system [14]. Group 5: Advantages of ProteanFect - ProteanFect offers three core advantages: 1. Superior delivery efficiency, especially in hard-to-transfect cell models, ensuring experimental precision [17]. 2. Lower cytotoxicity, preserving cell viability and natural function, which enhances data reliability [17]. 3. User-friendly convenience, with a straightforward protocol that reduces experimental time and increases reproducibility [17]. Group 6: Future Prospects - The development of ProteanFect is just the beginning, with ongoing exploration of its potential across various nucleic acid types and complex models, moving towards a new phase of gene delivery that aligns more closely with biological realities [19].

Core Insights - The study published in the journal "Cell" reveals that melanoma cells secrete large extracellular vesicles (melanosomes) that express major histocompatibility complex (MHC) molecules, which stimulate CD8+ T cells through T cell receptors (TCR), leading to T cell dysfunction and apoptosis [3] Group 1: Immune Evasion Mechanism - Melanoma cells utilize MHC export to protect themselves from cytotoxic T cell attacks, revealing a novel immune evasion mechanism [3][7] - The research indicates that melanosomes carry tumor-associated antigens with higher affinity and immunogenicity, competing directly with TCR-MHC interactions [3] Group 2: Impact of Inhibiting Melanosome Secretion - Inhibition of melanosome secretion significantly reduces tumor immune evasion, enhancing the effectiveness of CD8+ T cells in the tumor microenvironment [3][7] - The use of the depigmenting agent kojic acid, which blocks melanin production, resulted in decreased melanosome secretion without affecting melanoma proliferation or MHC I expression [4][5] Group 3: Experimental Findings - In mouse models, the inhibition of melanosome secretion led to increased infiltration of CD8+ T cells into the tumor microenvironment and slowed tumor growth [5][7] - The study demonstrates that blocking melanosome secretion can enhance the activity and effectiveness of tumor-infiltrating CD8+ T cells [7]

Core Viewpoint - Cuprina Holdings reported a decrease in revenue and an increase in net loss for the first half of 2025, but highlighted significant advancements in product diversification and geographic expansion [2]. Financial Performance - Revenue for the six months ended June 30, 2025, was $18.04 million, down 40% from $30.18 million in the same period last year, primarily due to lower sales of cosmeceutical and MEDIFLY MDT products [9]. - Gross profit was $302, with a gross margin declining to 1.7% from 44.8% year-over-year, reflecting fixed production costs amid reduced sales volume [9]. - Operating expenses increased by 163% year-over-year to $1,559,535, driven by higher professional fees for capital raising and consultancy [10]. - Net loss for the period was $1,528,121, or $(0.08) per share, compared to a net loss of $518,238, or $(0.03) per share, for the same period in 2024 [10]. - Cash and cash equivalents at June 30, 2025, were $3,216,540, supported by IPO proceeds, compared to $85,622 at December 31, 2024 [11]. Diversification and Expansion Achievements - In May 2025, the company completed construction of an IVF media production facility in Singapore, which is expected to commence commercial sales by Q4 2026 upon regulatory approval [3]. - Cuprina MENA Co. Ltd, a 49%-owned associate, set up a laboratory in Saudi Arabia for manufacturing MEDIFLY MDT products, with plans to begin supplying these products in the MENA region after regulatory approval [4]. - The company secured an FDA-approved license to market medical maggots in the U.S. in July 2025 [5]. - Cuprina obtained exclusive licensing rights to Southeast Asia's first medical waste recycling technology, which aims to transition from incineration to a sustainable model [6]. - A Memorandum of Understanding was signed with Singapore Biowaste Solutions Pte Ltd to integrate Cuprina's medical waste recycling technology into existing waste management facilities [7]. - In November 2025, a joint venture agreement was signed with Aiodine Laboratory to develop and market an iodine-based disinfectant solution for wound treatment [8]. Strategic Initiatives for 2026 - The company anticipates 2026 to be its most active commercial year, with multiple revenue streams expected to advance in parallel [14]. - Growth is projected to be driven by the MEDIFLY MDT business, with expansion into new clinical markets and increased hospital adoption, particularly in the Middle East [14]. - Cuprina plans to commercialize its medical waste recycling technology in partnership with SBS, aiming for recurring revenue [15]. - The company will also advance its amphibian collagen platform through human clinical trials to evaluate its efficacy in wound healing [15]. - To support these initiatives, Cuprina aims to strengthen its organizational leadership and internal capabilities by onboarding top talent and collaborating with industry experts [16]. - Total revenue for 2026 is projected to be between $1.0 million and $1.5 million [17].

Core Insights - Impossible Dream Machine has partnered with Parkland Center for Clinical Innovation (PCCI) to enhance healthcare solutions [1] Group 1 - The partnership aims to leverage innovative technologies to improve clinical outcomes [1] - This collaboration is expected to focus on data-driven approaches to address healthcare challenges [1] - The initiative will likely involve the development of new tools and methodologies for healthcare providers [1]